-+ 0.00%
-+ 0.00%
-+ 0.00%

Alport Syndrome Market to Grow at a Tremendous 47% CAGR Through 2036, Driven by Emerging Therapies and Expanding Clinical Pipeline | DelveInsight

Barchart·07/14/2026 09:31:00
Listen to the news

The Alport syndrome market is expected to witness significant growth over the coming years, driven by advancements in genetic diagnostics, increasing disease awareness, and the introduction of targeted therapies such as ELX-02 (Exaluren) (Eloxx Pharmaceuticals), Vonafexor (Enyo Pharma), BAY3401016 (Evotec and Bayer), Setanaxib (Asahi Kasei), Atrasentan (VANRAFIA) [Novartis (Chinook Therapeutics)], and others.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.